Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Pyrilutamide's inconsistent trial results, with phase II showing positive hair growth and phase III failing to show significant gains, possibly due to COVID-related disruptions. Users discuss modest results from kx-826 treatment.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

The user switched from finasteride to 2.5 mg dutasteride daily and added 1% pyrilutamide to address persistent scalp itch, but the itch remains. They also use 2% ketoconazole and 2.5% selenium sulfide shampoo for temporary relief.

A user is asking if Dutasteride can be effective when Finasteride has not stopped hair follicle miniaturization, despite having non-aggressive hair loss. The user has been using Finasteride for 2.5 years without success.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

User is considering switching from finasteride to dutasteride and adding pyrilutamide for hair loss treatment. Other users recommend dutasteride for its effectiveness and suggest adding pyrilutamide.

The user is considering adding low-level laser therapy (LLLT) to their hair loss treatment routine, which already includes minoxidil, finasteride, and microneedling. They are debating between purchasing a cheaper LLLT device or investing in a more expensive, clinically-backed option, with concerns about the effectiveness and specifications of cheaper models.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

0.5mg dutasteride reduces scalp DHT more than 1mg finasteride, leading to better hair regrowth results. Users report significant improvement with dutasteride compared to finasteride.

The user switched from finasteride to dutasteride and experienced noticeable hair regrowth without side effects, though some users questioned the necessity of such a potent treatment given the minimal hair loss. The conversation also touched on potential side effects of dutasteride, such as reduced sperm quality, but the user reported no issues.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

Dutasteride and finasteride for hair loss, with dissatisfaction expressed about dutasteride and consideration of switching back to finasteride. Users share varied experiences, noting individual responses to treatments differ.

People are discussing early results of the grey market hair loss treatment PP405. They mention previous attempts with jxl069 and interest in PP30.

The conversation is about purchasing dutasteride capsules from India and concerns about high temperatures affecting their efficacy. Users suggest that medicines are stored in cool conditions and recommend gel capsules over tablets.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Pyrilutamide is considered by some as an alternative for those avoiding 5AR inhibitors like finasteride and dutasteride, but opinions on its effectiveness vary. Some users report similar results with fluridil and pyrilutamide, while others find pyrilutamide less effective compared to prescription treatments.

PP405 aims to reactivate hair follicle stem cells to promote hair growth, but its effectiveness is debated. Some users are skeptical, citing past failures of similar treatments and questioning the company's claims.

Follicusan DP is discussed as a potential alternative to Minoxidil without side effects, but information is scarce. It is noted to be of German origin and details on its mechanism are limited.

Switching from finasteride to dutasteride led to hair density loss, prompting consideration of returning to finasteride. Consistency with dutasteride and adding RU58841 did not prevent the loss, and users suggest giving dutasteride more time or consulting a dermatologist.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

People have reported hair thickening with Pyrilutamide, particularly using a 1% concentration. Some users are curious about the availability of different concentrations like 0.9%.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

PP405 is progressing rapidly through trials, with mixed opinions on its potential effectiveness. Current treatments like minoxidil and finasteride are still widely discussed, with some users reporting positive results from new formulations.

Amplifica is developing new molecules for hair growth, with clinical trials expected soon, while Engraft Technologies is improving FUE robotic technology to make hair transplants faster and cheaper. Users express interest in the timeline for AMP-303 and concerns about high costs and effectiveness of current treatments.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

The conversation is about trying DS Labs SOD supplements for hair loss, which contain ingredients like Genistein, B-sitosterol, and Biotin. The user is considering adding these supplements to their existing hair care routine.